Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Compound pefusion for anti bladder cancer

A perfusate, bladder cancer technology, applied in antitumor drugs, drug combinations, bacterial antigen components, etc., can solve the problems of unsatisfactory clinical efficacy, poor patient compliance, unsatisfactory effects, etc., to improve the anticancer effect, toxic and side effects Reduced, increased patient compliance

Inactive Publication Date: 2005-01-12
沈周俊 +1
View PDF0 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] However, clinically, about 30% of patients treated and prevented with BCG still have unsatisfactory results. At the same time, most patients have side effects such as fever, frequent urination, urgency, painful urination, and hematuria after BCG infusion. Patients may even have severe toxic side effects such as high fever, liver tuberculosis, pulmonary tuberculosis, and bladder contraction
Therefore, the current use of BCG intravesical infusion to prevent tumor recurrence and progression has two shortcomings: (1) the clinical efficacy is still not satisfactory and needs to be improved; (2) there are many toxic and side effects, and the patient's compliance is poor

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0025] Animal experiments based on different injury modes of the bladder wall of rabbits, i.e. cutting injury, electrical burn, and freezing injury, found that the addition of coagulant PAMBA and EACA to the bladder perfusion of BCG can significantly improve the combination of BCG and the bladder wall. Compared with the simple BCG perfusion in the control group, the BCG binding amount increased by about 2.3 times, and the statistical test results had a very significant difference, P<0.001.

[0026] Perfusate group

example 2

[0028] In the clinical study, we selected 136 patients with transitional cell carcinoma of the bladder as research objects, and used the compound perfusion solution for regular bladder perfusion after surgery. The specific scheme is shown in Table 2. After 6-24 months of follow-up, compared with 20 cases of simple BCG perfusion in the control group, the recurrence and progression of bladder cancer can be significantly reduced. The effective rate of the new BCG perfusion solution is 89.6%, and that of the control group is 70.0%.

[0029] In conjunction with table 2, describe the concrete scheme of the present invention:

[0030] Fifty-six patients with primary superficial bladder cancer with cancer cell differentiation degree I-II were selected and divided into three groups, with 18 cases in the first group, 18 cases in the second group, 20 cases in the third group, and 20 cases in the third group. One group of patients chooses the compound perfusate of Group 1 in Table 2, the ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

A composite perfusate for treating urinary bladder cancer is prepared from BCG vaccine, coagulant (PAMBA or EACA) and physiological saline.

Description

technical field [0001] The invention relates to a compound perfusate drug for anti-bladder cancer in clinical medicine. Background technique [0002] Bladder transitional carcinoma is the most common malignant tumor of the urinary system in my country, and it is prone to recurrence and progression after surgery. Therefore, it is necessary to regularly perform bladder inspection with mitomycin, doxorubicin, thiotegua, bacillus Calmette-Guerin (BCG) and other drugs after surgery. [0003] Perfusion to prevent tumor recurrence, and BCG is considered the most effective drug in the current state of the art. The method is: at room temperature, 120mg BCG freeze-dried powder is 5×10 6 Colonies / mg Dissolved in 40-60ml of normal saline for intravesical perfusion and retained for 2 hours. Generally, perfusion starts 1-2 weeks after operation, once a week, and then changed to once a month after 6 consecutive times, and lasts for more than 2 years. [0004] However, clinically, about...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K39/04A61K47/16A61P35/00
Inventor 沈周俊丁国庆陆颖理
Owner 沈周俊
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com